In an interventional clinical trial evaluating sixty stroke patients with dominant-hemisphere upper-limb spasticity, researchers determined that administering botulinum toxin type A injections within three months of stroke onset produced significantly greater functional recovery and muscle tone reduction than delaying treatment beyond six months. Although participants across both early and delayed therapeutic arms achieved statistically significant improvements across all recorded clinical metrics compared to baseline, individuals receiving early intervention demonstrated substantially superior reductions in spasticity, greater improvements in voluntary motor performance, higher levels of independence in daily activities, and superior achievement of individualized rehabilitation goals. Furthermore, correlational analysis demonstrated that longer delays between stroke onset and botulinum toxin administration were strongly associated with higher post-treatment spasticity scores and poorer functional outcomes.
Post-stroke spasticity represents a defining component of upper motor neuron syndrome, occurring after acute central nervous system lesions disrupt descending neural pathways and diminish inhibitory control over spinal reflex circuits. Recognized globally as the second-leading cause of death and the third-leading cause of disability, cerebrovascular stroke frequently impairs upper extremity control, leaving most survivors with substantial hand impairment. Clinical data demonstrate that spasticity arises early, affecting roughly 19 percent of patients within three months and approximately 33 percent within twelve months. Furthermore, earlier cohort findings indicate that 87 percent of stroke patients lacking voluntary upper limb movement develop spasticity within six weeks. Left untreated, hypertonicity restricts motor recovery and promotes structural contractures. While guidelines endorse botulinum toxin type A for spasticity, most existing trials have examined chronic stroke populations.
The interventional clinical investigation was carried out from July 2024 to March 2025 following institutional ethical committee approval in compliance with the Declaration of Helsinki. Eligible participants were adults aged 18 to 70 years of both sexes with stroke confirmed by CT or MRI brain imaging affecting their dominant cerebral hemisphere. All enrolled patients exhibited clinically meaningful upper limb spasticity in at least one muscle group according to the Modified Ashworth Scale, while retaining preserved volitional movement in antagonist muscles. Candidate exclusion criteria encompassed existing upper limb joint deformities, fixed structural contractures, bilateral or recurrent stroke episodes, prior botulinum toxin administration or surgical spasticity treatments, pregnancy, breastfeeding, known drug allergies, and cognitive conditions interfering with rehabilitation. Recruited participants were selected from inpatient and outpatient units of the physical medicine department. Out of seventy-two candidates evaluated, twelve were excluded, consisting of ten patients disqualified due to inconsistent rehabilitation attendance and two who withdrew voluntarily, leaving sixty completed participants.
The final cohort was divided equally into two distinct groups of thirty patients based upon time elapsed since their initial stroke. Early Group 1 enrolled thirty subjects who presented within three months of stroke onset, while Late Group 2 enrolled thirty individuals presenting six months or more following stroke. Hemorrhagic stroke occurred in 35 of the 60 patients, representing 58.33 percent of the entire sample, with 16 cases in Group 1 and 19 cases in Group 2, showing no statistically significant variation between cohorts. Demographic metrics and baseline physical features were well matched across treatment arms. Initial evaluations revealed no significant differences in functional scores, disability indices, or spasticity across most muscle groups, with the sole exception of wrist flexor spasticity, which was significantly higher at baseline in Group 2 due to chronic duration.
Intramuscular injections followed World Health Organization guidelines, employing single-session ultrasound-guided delivery performed by a blinded experienced physician. Anatomical targets and dosage levels were customized based upon individual spasticity patterns, functional interference, and muscle size. Common dosing ranges encompassed 100 to 200 units for the biceps brachii, 25 to 75 units each for flexor digitorum superficialis and profundus, 25 to 50 units each for flexor carpi radialis, flexor carpi ulnaris, and pronator teres, and 5 to 30 units for flexor pollicis longus and adductor pollicis. The toxin was reconstituted in 2 milliliters of normal saline, producing a concentration of 5 units per 0.1 milliliter. Injections were administered slowly through 27-gauge to 30-gauge needles, dividing total doses across one to two points in small muscles and three to five points in large muscles. Total toxin doses were matched between cohorts, with only the adductor pollicis injected more often in Group 2. Pre-existing antispastic medications remained unchanged throughout the trial.
Following injection, all patients completed an identical multidisciplinary rehabilitation program designed to preserve range of motion and stimulate functional neuroplasticity. The post-injection protocol combined passive and active range-of-motion exercises to maintain joint mobility and prevent contracture formation, supported by targeted muscle stretching and daytime splinting of spastic muscles to improve muscle length. Rehabilitation incorporated intensive occupational therapy focusing on functional daily tasks, such as dressing, handwriting, buttoning clothing, grasping cups, and opening doors or bottles. Patients engaged in repetitive, goal-oriented motor activities to facilitate central nervous system relearning. Functional achievement was evaluated using the Goal Attainment Scale, tracking predefined personal milestones including facilitating upper-body dressing with under 50 percent assistance, improving dynamic arm carrying angle from 25 degrees toward 0 degrees during walking, and reducing resting and motion-induced pain to below 4 on a 10-point visual analogue scale, with scores ranging from minus 2 to plus 2.
The primary study outcome focused on functional independence changes from baseline to four weeks post-injection, measured by the Shah Modified Barthel Index on a 0-to-100 scale. Secondary endpoints evaluated muscle tone via the 6-point Modified Ashworth Scale, motor performance through the 18-point Upper Limb subscale of the Motor Assessment Scale, and disability through the Four-Point Disability Scale covering hygiene, dressing, limb positioning, and pain. Subjective global outcomes were rated four weeks post-injection using Patient, Physician, and Caregiver Global Assessments on a scale ranging from minus 4 to plus 4. Sample size was established using G-Power software based on prior data from Lim and colleagues, determining that thirty subjects per group provided 80 percent statistical power at a 95 percent confidence level, with initial enrolment inflated by 20 percent to accommodate dropouts. Statistical analysis utilized SPSS version 26, applying Student’s t-tests, Mann-Whitney tests, and Chi-square analyses with significance set at P < 0.05.
Four weeks post-injection, both groups exhibited statistically significant improvements across all assessed parameters compared to baseline (P < 0.001). However, Group 1 demonstrated statistically significantly greater improvements across all outcome measures compared to Group 2 (P < 0.05). Significant 95 percent confidence intervals were confirmed when comparing post-injection wrist flexor Modified Ashworth Scale scores, Upper Limb Motor Assessment Scale scores, and Barthel Index performance between cohorts. Subjective ratings also favored early administration, as Group 1 achieved significantly greater overall improvements in Patient Global Assessment (P = 0.002), Physician Global Assessment (P = 0.001), and Caregiver Global Assessment (P = 0.001). Evaluating predefined goals using the Goal Attainment Scale revealed significantly higher scores in Group 1 (P < 0.001) for easing assisted dressing, improving arm carrying angles, and reducing pain. Correlation analyses showed that stroke duration was positively correlated with post-injection spasticity and disability, but negatively correlated with motor assessment and Barthel scores (P < 0.001).
Adverse events following botulinum toxin injection were mild, transient, and demonstrated no statistically significant differences between early and delayed groups. Post-injection complications were limited to localized injection-site pain, swelling, and minor bruising, with no participants experiencing lasting sequelae. Specifically, pain affected 14 patients (46.67 percent) in Group 1 and 12 patients (40.00 percent) in Group 2, while localized swelling occurred in 7 patients (23.33 percent) in Group 1 and 9 patients (30.00 percent) in Group 2. Bruising was observed in 1 patient (3.33 percent) in Group 2 and was entirely absent in Group 1. These safety observations align with previous clinical investigations by Rosales and colleagues and Ismail and colleagues, confirming favorable tolerability profiles. Furthermore, the substantial spasticity reductions observed across both ischemic and hemorrhagic stroke subtypes confirm established findings that botulinum neurotoxin effectively provides chemodenervation regardless of underlying stroke pathology.
The researchers concluded that early administration of botulinum toxin type A within three months of stroke onset achieves superior functional recovery by exploiting an early window of heightened neuroplasticity. Early spasticity reduction preserves joint mobility and prevents structural contractures, establishing conditions necessary for effective motor relearning during post-injection rehabilitation. Conversely, delayed treatment in chronic stages encounters established structural stiffness and learned non-use, explaining why late spasticity reduction often fails to yield comparable active motor recovery. Despite these positive outcomes, the authors identified several study limitations, including a small sample size of sixty participants, a single-center design, and a four-week post-injection follow-up timeframe. They emphasized that tone reduction alone does not guarantee functional improvement without adherence to structured rehabilitation and recommended that future large-scale, multicenter trials with extended follow-up evaluate long-term outcomes of early botulinum toxin interventions in stroke rehabilitation.
Subject of Research: Comparative clinical efficacy of early versus delayed botulinum toxin type A injections for post-stroke upper limb spasticity and motor recovery
Article Title: Effectiveness of Early Botulinum Toxin Injections on Upper Limb Spasticity versus after 6 months post stroke
Article References: Abdelmoneam, A. G., Darwish, H., Ali, A. E., Abo Nar, E.-N. N., Ahmed, H. N., & Gergius, Y. S. (2026). Effectiveness of Early Botulinum Toxin Injections on Upper Limb Spasticity versus after 6 months post stroke. Egyptian Rheumatology and Rehabilitation, 53(1), Article 42. https://doi.org/10.1186/s43166-026-00411-2
Image Credits: AI Generated
DOI: 10.1186/s43166-026-00411-2
Keywords: Botulinum toxin type A, Post-stroke spasticity, Upper limb rehabilitation, Stroke recovery, Modified Ashworth scale, Barthel index, Motor Assessment Scale, Disability Assessment Scale, Goal Attainment Scale, Chemodenervation, Ultrasound-guided injection, Muscle tone, Occupational therapy, Neuroplasticity, Hemiparesis, Range of motion, Upper motor neuron syndrome
News Source: Cassandra Pierce. (November 13, 2026). Early Botulinum Toxin Injection Improves Upper Limb Recovery Following Stroke. Scienmag.



